Molecular profiling of tumors
Provided herein are methods and systems of molecular profiling of diseases, such as cancer. In some embodiments, the molecular profiling can be used to identify treatments for a disease, such as treatments that were not initially identified as a treatment for the disease or not expected to be a treatment for a particular disease.
1 . A computer system comprising:
one or more processors; and
computer memory that is in communication with the one or more processors and stores instructions that, when executed by the one or more processors, perform operations comprising:
obtaining data that is indicative of results of a performance of one or more molecular tests for a plurality of molecular profiling targets of a biological sample obtained from a patient that has a particular cancer type, wherein the one or more molecular tests comprise at least one selected from a group consisting of gene expression analysis and nucleic acid sequence analysis;
accessing, without using the particular cancer type, a first database of the computer system to obtain corresponding reference values;
comparing the obtained data to the corresponding reference values obtained from the first database of the computer system, wherein the corresponding reference values are not associated with the particular cancer type in the first database as part of the comparing;
accessing the first database or another database to identify, from the comparing, at least one therapeutic agent based on an indication that the comparison indicates a likely benefit to the patient of the at least one therapeutic agent; and
generating a patient profile report that presents the at least one therapeutic agent as a suitable agent for the patient.
2 . The computer system of claim 1 , wherein accessing the first database or the other database to identify the at least one therapeutic agent is performed independent of the particular cancer type.
3 . The computer system of claim 1 , wherein the operations further comprise:
providing the patient profile report to an end user.
4 . The computer system of claim 1 , wherein the at least one therapeutic agent of the patient profile report includes a therapeutic agent that is not a standard of care for the particular cancer type.
5 . The computer system of claim 1 , wherein the at least one therapeutic agent of the patient profile report includes a drug therapy capable of interacting with at least one of the plurality of molecular profiling targets.
6 . The computer system of claim 5 , wherein the at least one of the plurality of molecular profiling targets exhibited a change in expression relative to a corresponding reference value.
7 . The computer system of claim 1 , the operations further comprising:
comparing the obtained data to corresponding additional reference values stored in a second database of the computer system, wherein the corresponding additional reference values are associated with one or more particular cancer type as part of the comparing;
identifying, from the comparing to the corresponding additional reference values, at least one additional therapeutic agent based on an indication that the comparison indicates a likely benefit to the patient of the at least one additional therapeutic agent, wherein the identifying is performed by taking into account an association between the at least one additional therapeutic agent and one or more particular cancer types; and
wherein generating the patient profile report comprises:
including the at least one additional therapeutic agent as a suitable agent for the patient within the patient profile report.
8 . The computer system of claim 1 , wherein the corresponding reference values in the first database were determined and are stored without regard to associations between particular reference values and particular cancer types.
9 . The computer system of claim 1 , wherein the at least one therapeutic agent is identified based solely on comparing the data obtained for the molecular profiling targets and without regard to an association with any particular cancer type.
10 . The computer system of claim 1 , wherein the plurality of molecular profiling targets include ERBB2, ESR1, KIT, TOP1, and EGFR, and wherein the corresponding reference values comprise reference values for ERBB2, ESR1, KIT, TOP1, and EGFR.
11 . The computer system of claim 1 , wherein the biological sample comprises tumor tissue or a bodily fluid.
12 . The computer system of claim 11 , wherein the bodily fluid comprises blood, cell extracts, nuclear extracts, cell lysates, excretions, sera, plasma, urine, sputum, tears, feces, saliva, or membrane extracts.
13 . The computer system of claim 1 , wherein the corresponding reference values include a reference value associated with at least one individual that does not have cancer.
14 . The computer system of claim 1 , wherein the molecular profiling targets comprise nucleic acids and/or proteins.
15 . The computer system of claim 1 , wherein the one or more molecular tests comprise a microarray, genotyping, and/or proteomic analysis of the biological sample from the patient.
16 . The computer system of claim 1 , wherein the operations further comprise:
identifying, from the comparing of the obtained data to the corresponding reference values, at least one non-beneficial therapeutic agent that is not likely benefit to the patient; and
including the at least one non-beneficial therapeutic agent within the patient profile report.
17 . The computer system of claim 7 , wherein the operations further comprise:
identifying, from the comparing of the obtained data to the corresponding additional reference values, at least one non-beneficial therapeutic agent that is not likely benefit to the patient; and
including the at least one non-beneficial therapeutic agent within the patient profile report.
18 . The computer system of claim 1 , wherein the one or more molecular tests comprise at least one of polymerase chain reaction (PCR), pyrosequencing, real-time PCR, sequencing, NextGen sequencing, methylation specific PCR (MSPCR), restriction fragment length polymorphism (RFLP) analysis, immunohistochemistry (IHC), immunoassay, an expression microarray, a comparative genomic hybridization (CGH) microarray, a single nucleotide polymorphism (SNP) microarray, in-situ hybridization (ISH), fluorescent in-situ hybridization (FISH), and a proteomic array.
19 . The computer system of claim 1 , wherein the one or more molecular tests are configured to identify at least one of a mutation, polymorphism, deletion, insertion, substitution, translocation, fusion, break, duplication, amplification or repeat in a nucleic acid sequence corresponding to at least one of the molecular profiling targets.
20 . The computer system of claim 1 , wherein the one or more molecular tests include a plurality of molecular tests and comprise a nucleic acid methylation analysis.
21 . The computer system of claim 1 , wherein the particular cancer type is of breast, liver, colon, ovarian, lung, pancreas, lymph nodes, bladder, rectum, or prostate.
22 . A method comprising:
obtaining, by a computer system, data that is indicative of results of a performance of one or more molecular tests for a plurality of molecular profiling targets of a biological sample obtained from a patient that has a particular cancer type, wherein the one or more molecular tests comprise at least one selected from a group consisting of gene expression analysis and nucleic acid sequence analysis;
accessing, by the computer system without using the particular cancer type, a first database of the computer system to obtain corresponding reference values;
comparing, by the computer system, the obtained data to the corresponding reference values obtained from the first database of the computer system, wherein the corresponding reference values are not associated with the particular cancer type in the first database as part of the comparing;
accessing, by the computer system, the first database or another database to identify, from the comparing, at least one therapeutic agent based on an indication that the comparison indicates a likely benefit to the patient of the at least one therapeutic agent; and
generating, by the computer system, a patient profile report that presents the at least one therapeutic agent as a suitable agent for the patient.
23 . The method of claim 22 , wherein accessing the first database or the other database to identify the at least one therapeutic agent is performed independent of the particular cancer type.
24 . The method of claim 22 , wherein the at least one therapeutic agent of the patient profile report includes a therapeutic agent that is not a standard of care for the particular cancer type.
25 . The method of claim 22 , wherein the at least one therapeutic agent of the patient profile report includes a drug therapy capable of interacting with at least one of the plurality of molecular profiling targets.
26 . The method of claim 25 , wherein the at least one of the plurality of molecular profiling targets exhibited a change in expression relative to a corresponding reference value.
27 . The method of claim 22 , further comprising:
comparing the obtained data to corresponding additional reference values stored in a second database of the computer system, wherein the corresponding additional reference values are associated with one or more particular cancer type as part of the comparing;
identifying, from the comparing to the corresponding additional reference values, at least one additional therapeutic agent based on an indication that the comparison indicates a likely benefit to the patient of the at least one additional therapeutic agent, wherein the identifying is performed by taking into account an association between the at least one additional therapeutic agent and one or more particular cancer types; and
wherein generating the patient profile report comprises:
including the at least one additional therapeutic agent as a suitable agent for the patient within the patient profile report.
28 . The method of claim 22 , wherein the corresponding reference values in the first database were determined and are stored without regard to associations between particular reference values and particular cancer types.
29 . The method of claim 22 , wherein the at least one therapeutic agent is identified based solely on comparing the data obtained for the plurality of molecular profiling targets and without regard to an association with any particular cancer type.
30 . One or more non-transitory computer-readable storage medium storing instructions that, when executed by one or more computers, cause the one or more computers to perform operations, the operations comprising:
obtaining data that is indicative of results of a performance of one or more molecular tests for a plurality of molecular profiling targets of a biological sample obtained from a patient that has a particular cancer type, wherein the one or more molecular tests comprise at least one selected from a group consisting of gene expression analysis and nucleic acid sequence analysis;
accessing, without using the particular cancer type, a first database of the one or more computers to obtain corresponding reference values;
comparing the obtained data to the corresponding reference values obtained from the first database of the one or more computers, wherein the corresponding reference values are not associated with the particular cancer type in the first database as part of the comparing;
accessing the first database or another database to identify, from the comparing, at least one therapeutic agent based on an indication that the comparison indicates a likely benefit to the patient of the at least one therapeutic agent; and
generating a patient profile report that presents the at least one therapeutic agent as a suitable agent for the patient.
31 . The one or more non-transitory computer-readable storage medium of claim 30 , wherein accessing the first database or the other database to identify the at least one therapeutic agent is performed independent of the particular cancer type.
32 . The one or more non-transitory computer-readable storage medium of claim 30 , wherein the at least one therapeutic agent of the patient profile report includes a therapeutic agent that is not a standard of care for the particular cancer type.
33 . The one or more non-transitory computer-readable storage medium of claim 30 , wherein the at least one therapeutic agent of the patient profile report includes a drug therapy capable of interacting with at least one of the plurality of molecular profiling targets.